Back to search results

Phase Ib Study of Avutometinib, Defactinib, and Everolimus for RAS Pathway Mutant Endometrial Cancer

This study is testing a combination of three drugs: avutometinib, defactinib, and everolimus, for women with recurrent endometrial cancer that has specific changes in the RAS pathway genes (like KRAS, NRAS, HRAS, BRAF, MEK1, or MEK2). The main goal is to find the safest and most effective dose of these three drugs when given together. Researchers will also look at any side effects you might experience. To join, you must have endometrial cancer that has come back and has these specific gene changes. The study plans to enroll 31 participants.

Study design
This is a Phase Ib interventional study, meaning it's an early-stage trial focused on safety and dosing. It plans to enroll 31 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07318324

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Recruiting
PHASE1Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~31 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:AvutometinibdefactinibEverolimus

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and adverse events (AEs).
Measured over Through study completion; an average of 1 year

Conditions

Phase IB
Avutometinib
RAS Pathway
Endometrial

Explore related trials

Endometrial CarcinomaBRAF GeneGTPase KRasHRAS GeneMitogen-Activated Protein Kinase KinaseNRAS Gene

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Shannon N Westin, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Shannon N Westin, MD
[email protected]
713-794-4314
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Strong CYP3A4 inhibitors or inducers
Strong CYP2C9 inhibitors or inducers
Strong P-glycoprotein (P-gp) inhibitors or inducers
Strong breast cancer resistance protein (BCRP) inhibitors or inducers 21. Specific concurrent ocular disorders:
History of glaucoma, history of retinal vein occlusion (RVO), predisposing factors for RVO, including uncontrolled hypertension, uncontrolled diabetes
History of retinal pathology or evidence of visible retinal pathology that is considered a risk factor for RVO, intraocular pressure \> 21 mmHg as measured by tonometry, or other significant ocular pathology, such as anatomical abnormalities that increase the risk for RVO.
Active or chronic, visually significant corneal disorders, other active ocular conditions requiring ongoing therapy, or clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy. Examples of visually significant corneal disorders include corneal degeneration, active or recurrent keratitis, and other forms of serious ocular surface inflammatory conditions. Visually significant corneal disorders do NOT include dry eyes, blepharitis, and uncomplicated corneal erosions. 22. Severe skin disorder in the opinion of treating MD that has required systemic therapy within one year of the first dose of study intervention.

What this trial measures

  • Safety and adverse events (AEs).Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0